Researchers from the University of Hong Kong have developed a new oral formulation of arsenic trioxide to treat acute promyelocytic leukaemia patients. The treatment called Oral-ATO can help some patients avoid having to undergo chemotherapy or bone marrow transplants and offers a 97 per cent cure rate. The Post’s Jayson Albano speaks with the study’s lead investigator, Dr Harinder Gill, about the significance of the new treatment.